REMEGEN

🇭🇰Hong Kong, China

Country: 🇭🇰Hong Kong, China

Ownership: Public

Established: 2008-07-04

Employees: 3.4K

Market Cap: -

Website: http://www.remegen.com

Introduction: The company was co-founded in 2008 by Yantai Rongchang Pharmaceutical Co., Ltd., headed by Mr. Wang Weidong, and American scientist Dr. Fang Jianmin. The company is committed to discovering, developing, producing and commercializing first-of-its-kind, best-in-class biopharmaceuticals, and creating a number of new biological drugs with significant clinical va...

Clinical Trials

A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis

Phase 2

Completed

Conditions: Systemic Myasthenia Gravis

Interventions: Biological: RC18 160mg
Biological: RC18 240 mg

First Posted Date: 2020-03-10

Last Posted Date: 2023-10-11

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 29

Registration Number: NCT04302103

Locations: 🇨🇳
Beijing Tiantan Hospital,Capital Medical University, Beijing, Beijing, China

A Study of RC18 Administered Subcutaneously to Subjects With IgA(Immunoglobulin A) Nephropathy

Phase 2

Completed

Conditions: Primary IgA Nephropathy

Interventions: Biological: placebo
Biological: RC18 160mg
Biological: RC18 240mg

First Posted Date: 2020-03-02

Last Posted Date: 2021-07-19

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 44

Registration Number: NCT04291781

Locations: 🇨🇳
Peking University First Hospital., Beijing, Beijing, China

Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration

Phase 1

Completed

Conditions: Wet Age-Related Macular Degeneration

Interventions: Biological: intravitreal injection of RC28-E 0.5mg
Biological: intravitreal injection of RC28-E 1.0mg
Biological: intravitreal injection of RC28-E2.0mg

First Posted Date: 2020-02-17

Last Posted Date: 2022-01-10

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 37

Registration Number: NCT04270669

Locations: 🇨🇳
Beijing Hospital, Beijing, Beijing, China

A Phase I Study of TACI-antibody Fusion Protein Injection (RC18) in Healthy Adult Chinese Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: Tai Ai(RC18) 80mg
Biological: RC18 240mg
Biological: Tai Ai(RC18) 160mg

First Posted Date: 2020-01-22

Last Posted Date: 2020-01-22

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 36

Registration Number: NCT04235933

Locations: 🇨🇳
Remegen，ltd., Yantai, Shandong, China

A Study of RC98 in Subjects With Advanced Malignant Solid Tumors

Phase 1

Active, not recruiting

Conditions: Solid Tumors

Interventions: Drug: RC98

First Posted Date: 2019-12-09

Last Posted Date: 2023-11-27

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 63

Registration Number: NCT04190823

Locations: 🇨🇳
Tianjin Cancer Hospital, Tianjin, Tianjin, China

A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor

Interventions: Drug: RC88

First Posted Date: 2019-11-25

Last Posted Date: 2024-02-20

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 200

Registration Number: NCT04175847

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, Beijing, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
Drum Tower Hospital, Nanjing, Jiangsu, China

and more 1 locations

Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)

Phase 3

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Biological: Placebo plus standard therapy
Biological: RC18 160 mg plus standard therapy

First Posted Date: 2019-09-09

Last Posted Date: 2023-05-11

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 335

Registration Number: NCT04082416

Locations: 🇨🇳
Remegen，ltd., Yantai, Shandong, China

A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome

Phase 2

Completed

Conditions: Primary Sjögren's Syndrome

Interventions: Biological: RC18 240 mg
Biological: RC18 160 mg
Biological: Placebo

First Posted Date: 2019-09-06

Last Posted Date: 2022-01-11

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 42

Registration Number: NCT04078386

Locations: 🇨🇳
Remegen,Ltd., Yantai, Shandong, China

A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer

Phase 2

Completed

Conditions: Urothelial Carcinoma

Interventions: Drug: RC48-ADC

First Posted Date: 2019-08-29

Last Posted Date: 2023-12-18

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 19

Registration Number: NCT04073602

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer

Phase 2

Completed

Conditions: Urothelial Carcinoma

Interventions: Drug: RC48-ADC

First Posted Date: 2019-01-18

Last Posted Date: 2023-11-27

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 64

Registration Number: NCT03809013

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

and more 5 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy